Retrospective analysis of core-needle and vacuum-assisted breast biopsies of B3 fibroepithelial lesions and correlation with results in subsequent surgical specimens.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
28 Sep 2024
Historique:
received: 18 02 2024
accepted: 30 08 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Fibroepithelial lesions (FEL) are a heterogeneous group of biphasic tumours that include fibroadenomas (FA) and the rare entity of benign phyllodes tumors (PT) as well as cases where distinction between these two entities is not possible. The histologic distinction between benign PT and cellular FA is still a diagnostic challenge, especially in core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB). Guidelines are not clearly established regarding the management of FEL in CNB or VAB. In this study, we addressed the frequency of B3 FEL diagnosed in CNB or VAB and compared the final histopathological findings in the excision specimens to evaluate up- or downgrading. We identified 117 female patients with the preoperative diagnosis of FEL (B3), PT, or FEL in combination of pure epithelial B3 lesions in CNB or VAB. Clinico-pathological information as well as data on subsequent surgical excision were available for all patients. PT was diagnosed in 9 (14.8%) and FEL (B3) in 52 (85.2%) cases. Additionally, 56 patients with FA in combination with an additional B3 lesion were identified. Most FEL (B3)/PT initial diagnoses were made in CNB (55.6% of PT; 84.6% of FEL). After the initial biopsy, 7 of 9 (77.8%) patients with initial diagnosis of benign or borderline PT in CNB/VAB and 40 of 52 (77.0%) patients with initial diagnosis of FEL (B3) in CNB/VAB underwent open excision (OE). 4 of 9 cases (44.4%) initially diagnosed as PT were verified, whereas 2 of 9 (22.2%) were downgraded to FA. 20 of 52 cases (38.5%) initially diagnosed as FEL (B3) were downgraded to FA, whereas 11 of 52 cases (21.2%) were diagnosed as benign or borderline PT. One FEL (B3) case was upgraded to malignant PT. Most PT and FEL (B3) diagnoses on CNB/VAB underwent surgical removal. In the final pathological findings of cases classified primarily as FEL (B3), the majority were downgraded to FA, one quarter were upgraded to PT, and a small subset remained as combined FA/PT. In clinical daily practice, we recommend individualized decision-making considering different options (clinical follow-up or removal of the lesion depending on the whole context) in a multidisciplinary preoperative conference.

Sections du résumé

BACKGROUND BACKGROUND
Fibroepithelial lesions (FEL) are a heterogeneous group of biphasic tumours that include fibroadenomas (FA) and the rare entity of benign phyllodes tumors (PT) as well as cases where distinction between these two entities is not possible. The histologic distinction between benign PT and cellular FA is still a diagnostic challenge, especially in core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB). Guidelines are not clearly established regarding the management of FEL in CNB or VAB. In this study, we addressed the frequency of B3 FEL diagnosed in CNB or VAB and compared the final histopathological findings in the excision specimens to evaluate up- or downgrading.
METHODS METHODS
We identified 117 female patients with the preoperative diagnosis of FEL (B3), PT, or FEL in combination of pure epithelial B3 lesions in CNB or VAB. Clinico-pathological information as well as data on subsequent surgical excision were available for all patients.
RESULTS RESULTS
PT was diagnosed in 9 (14.8%) and FEL (B3) in 52 (85.2%) cases. Additionally, 56 patients with FA in combination with an additional B3 lesion were identified. Most FEL (B3)/PT initial diagnoses were made in CNB (55.6% of PT; 84.6% of FEL). After the initial biopsy, 7 of 9 (77.8%) patients with initial diagnosis of benign or borderline PT in CNB/VAB and 40 of 52 (77.0%) patients with initial diagnosis of FEL (B3) in CNB/VAB underwent open excision (OE). 4 of 9 cases (44.4%) initially diagnosed as PT were verified, whereas 2 of 9 (22.2%) were downgraded to FA. 20 of 52 cases (38.5%) initially diagnosed as FEL (B3) were downgraded to FA, whereas 11 of 52 cases (21.2%) were diagnosed as benign or borderline PT. One FEL (B3) case was upgraded to malignant PT.
CONCLUSION CONCLUSIONS
Most PT and FEL (B3) diagnoses on CNB/VAB underwent surgical removal. In the final pathological findings of cases classified primarily as FEL (B3), the majority were downgraded to FA, one quarter were upgraded to PT, and a small subset remained as combined FA/PT. In clinical daily practice, we recommend individualized decision-making considering different options (clinical follow-up or removal of the lesion depending on the whole context) in a multidisciplinary preoperative conference.

Identifiants

pubmed: 39340595
doi: 10.1007/s00432-024-05934-9
pii: 10.1007/s00432-024-05934-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

436

Informations de copyright

© 2024. The Author(s).

Références

Choi J, Koo JS (2012) Comparative study of histological features between core needle biopsy and surgical excision in phyllodes tumor. Pathol Int 62(2):120–126
doi: 10.1111/j.1440-1827.2011.02761.x pubmed: 22243782
Co M, Chen C, Tsang JY, Tse G, Kwong A (2018) Mammary phyllodes tumour: a 15-year multicentre clinical review. J Clin Pathol 71(6):493–497
doi: 10.1136/jclinpath-2017-204827 pubmed: 29146885
Dessauvagie BF, Lee AHS, Meehan K, Nijhawan A, Tan PH, Thomas J (2018) Interobserver variation in the diagnosis of fibroepithelial lesions of the breast: a multicentre audit by digital pathology. J Clin Pathol 71(8):672–679
doi: 10.1136/jclinpath-2017-204977 pubmed: 29440134
Elfgen C, Leo C, Kubik-Huch RA, Muenst S, Schmidt N, Quinn C (2023) Third international consensus conference on lesions of uncertain malignant potential in the breast lesions. Virchows Arch 483(1):5–20
doi: 10.1007/s00428-023-03566-x pubmed: 37330436 pmcid: 10326140
Krings G, Bean GR, Chen YY (2017) Fibroepithelial lesions; the WHO spectrum. Semin Diagn Pathol 34(5):438–452
doi: 10.1053/j.semdp.2017.05.006 pubmed: 28688536
Lawton TJ, Acs G, Argani P, Farshid G, Gilcrease M, Goldstein N (2014) Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol 22(8):695–698
doi: 10.1177/1066896914548763 pubmed: 25161205 pmcid: 4352312
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2021) S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. [zitiert 28. Januar 2024];(Version 4.4). Verfügbar unter: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
Marcil G, Wong S, Trabulsi N, Allard-Coutu A, Parsyan A, Omeroglu A (2017) Fibroepithelial breast lesions diagnosed by core needle biopsy demonstrate a moderate rate of upstaging to phyllodes tumors. Am J Surg 214(2):318–322
doi: 10.1016/j.amjsurg.2016.12.017 pubmed: 28057293
Mohan SC, Tseng J, Marumoto A, Angarita S, Dadmanesh F, Amersi F (2022) Upstaging of fibroepithelial lesions: a single-institution experience. Ann Surg Oncol 29(4):2193–2199
doi: 10.1245/s10434-021-10931-0 pubmed: 34671884
NCCN (2023) NCCN clinical practice guidelines in oncology (NCCN Guidelines ®) breast cancer, version 4.2023 [zitiert 5. Dezember 2023]. Verfügbar unter: https://www.nccn.org/guidelines/guidelines-detail
Ouyang Q, Li S, Tan C, Zeng Y, Zhu L, Song E (2016) Benign phyllodes tumor of the breast diagnosed after ultrasound-guided vacuum-assisted biopsy: surgical excision or wait-and-watch? Ann Surg Oncol 23(4):1129–1134
doi: 10.1245/s10434-015-4990-5 pubmed: 26577125
Resetkova E, Khazai L, Albarracin CT, Arribas E (2010) Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J 16(6):573–580
doi: 10.1111/j.1524-4741.2010.01013.x pubmed: 21070433
Sars C, Sackey H, Frisell J, Dickman PW, Karlsson F, Kindts I (2023) Current clinical practice in the management of phyllodes tumors of the breast: an international cross-sectional study among surgeons and oncologists. Breast Cancer Res Treat 199(2):293–304
doi: 10.1007/s10549-023-06896-1 pubmed: 36879102 pmcid: 9988205
Shaaban M, Barthelmes L (2017) Benign phyllodes tumours of the breast: (Over) treatment of margins–a literature review. Eur J Surg Oncol 43(7):1186–1190
doi: 10.1016/j.ejso.2016.10.019 pubmed: 27939569
Tan PH, Thike AA, Tan WJ, Thu MMM, Busmanis I, Li H (2012) Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 65(1):69–76
doi: 10.1136/jclinpath-2011-200368 pubmed: 22049216
Than PH, Tse G, Lee A, Simpson JF, Hanby AM (2012) Chapter 11-fibroepithelial tumours. WHO Classification of Tumours of the Breast 4th ed (World Health Organization Classification of Tumours). Lyon, International Agency for Research on Cancer, pp 141–147
Tse G, Koo J, Thike A (2019a) Phyllodes tumour. WHO Classification of Tumours Editorial Board Breast tumours (WHO classification of tumours series 5
Tse G, Shin S, Val-Bernal J (2019b) Fibroepithelial tumours and hamartomas of the breast: Introduction. WHO Classification of Tumours Editorial Board Breast Tumours Who Classification of Tumours series 5th ed, vol 2. Lyon, International Agency for Research on Cancer, p 165
Van Osdol AD, Landercasper J, Andersen JJ, Ellis RL, GenschJohnson EMJM (2014) Determining whether excision of all fibroepithelial lesions of the breast is needed to exclude phyllodes tumor: upgrade rate of fibroepithelial lesions of the breast to phyllodes tumor. JAMA Surg 149(10):1081–1085
doi: 10.1001/jamasurg.2014.73 pubmed: 25162470
Varga Z, Sinn P, Lebeau A (2023) B3-Läsionen der Mamma: Histologische, klinische und epidemiologische Aspekte. Pathol Heidelb Ger 44(1):5–16
doi: 10.1007/s00292-022-01180-3
Youk JH, Kim H, Kim EK, Son EJ, Kim MJ, Kim JA (2015) Phyllodes tumor diagnosed after ultrasound-guided vacuum-assisted excision: should it be followed by surgical excision? Ultrasound Med Biol 41(3):741–747
doi: 10.1016/j.ultrasmedbio.2014.11.004 pubmed: 25619780
Zhou ZR, Wang CC, Sun XJ, Yang ZZ, Yu XL, Guo XM (2016a) Diagnostic performance of core needle biopsy in identifying breast phyllodes tumors. J Thorac Dis 8(11):3139–3151
doi: 10.21037/jtd.2016.10.109 pubmed: 28066593 pmcid: 5179415
Zhou ZR, Wang CC, Yang ZZ, Yu XL, Guo XM (2016b) Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence. J Thorac Dis 8(11):3361–3368
doi: 10.21037/jtd.2016.11.03 pubmed: 28066617 pmcid: 5179374

Auteurs

Sophia Näther (S)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.
Department of Internal Medicine, Spital Zollikerberg, Zollikerberg, Switzerland.

Constanze Elfgen (C)

Breast Center Seefeld, Zurich, Switzerland.
University of Witten/Herdecke, Witten, Germany.

Ann-Katrin Rodewald (AK)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.

Hisham Fansa (H)

Breast Center, Spital Zollikerberg, Zollikerberg, Switzerland.

Heike Frauchiger-Heuer (H)

Breast Center, University Hospital Zurich, Zurich, Switzerland.
Comprehensive Cancer Center, University Hospital Zurich, Zurich, Switzerland.

Zsuzsanna Varga (Z)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland. zsuzsanna.varga@usz.ch.
Comprehensive Cancer Center, University Hospital Zurich, Zurich, Switzerland. zsuzsanna.varga@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH